Company Analysis
Sign in

Tyra Biosciences, Inc. (TYRA)

Nasdaq: TYRA · Pharmaceutical Preparations · Carlsbad, CA · filing with the SEC since 2021
Full chart Alerts Compare
Grade5.6
◀ Past 6.1● Present 5.9▶ Future 5.0
6 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

3 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Tyra Biosciences, Inc.’s names, not what it holds today.

Patents granted
3
3 utility, 1976 to Dec 31, 2025
Granted in 2025
2
Against 1 in 2024 and none in 2023
Applications published
9
3 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Organic fine chemistry2
Pharmaceuticals1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
TYRA BIOSCIENCES, INC. its own name
named as the applicant on its applications, in US
0 granted
9 published
TYRA BIOSCIENCES, INC. its own name
US, as the owner printed on each patent
3 granted
0 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Oct 14, 202512,441,707Indazole compoundsPharmaceuticalsTYRA BIOSCIENCES, INC.
Apr 1, 202512,264,149Indazole compounds as kinase inhibitorsOrganic fine chemistryTYRA BIOSCIENCES, INC.
Aug 27, 202412,071,428Indazole compounds as kinase inhibitorsOrganic fine chemistryTYRA BIOSCIENCES, INC.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Dec 4, 20252025/0368666INDAZOLE COMPOUNDSPharmaceuticalsTYRA BIOSCIENCES, INC.
Nov 13, 20252025/0345333THERAPIES WITH PPAR AGONISTS AND FGFR4 INHIBITORSPharmaceuticalsTYRA BIOSCIENCES, INC.
Nov 6, 20252025/0340533INDAZOLE COMPOUNDS AS KINASE INHIBITORSOrganic fine chemistryTYRA BIOSCIENCES, INC.
Sep 26, 20242024/0316022INDAZOLE COMPOUNDSOrganic fine chemistryTYRA BIOSCIENCES, INC.
Jun 27, 20242024/0208941INDAZOLE COMPOUNDS AS KINASE INHIBITORSOrganic fine chemistryTYRA BIOSCIENCES, INC. · patent 12,071,428 granted from it
Jun 13, 20242024/0190849AMINOPYRIMIDINE COMPOUNDS AND METHODS OF THEIR USEOrganic fine chemistryTYRA BIOSCIENCES, INC.
Apr 4, 20242024/0109865INDAZOLE COMPOUNDS AS KINASE INHIBITORSOrganic fine chemistryTYRA BIOSCIENCES, INC. · patent 12,264,149 granted from it
Apr 13, 20232023/0115945AMINOPYRIMIDINE COMPOUNDSOrganic fine chemistryTYRA BIOSCIENCES, INC.
Apr 13, 20232023/0115528INDAZOLE COMPOUNDSPharmaceuticalsTYRA BIOSCIENCES, INC. · patent 12,441,707 granted from it
What it applied for, 2024 to 2025: Organic fine chemistry 5 · Pharmaceuticals 2.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton TYRA · research, not advice